Reprogramming Cancer Immunity: Mechanistic Breakthroughs ...
2025-10-17
Explore how Lenalidomide (CC-5013) transcends conventional cancer immunotherapy by integrating advanced mechanistic insights, including recent discoveries on DOT1L inhibition and innate immune reprogramming. This thought-leadership article delivers strategic, workflow-oriented guidance for translational researchers, highlighting optimized protocols, competitive advantages, and visionary perspectives for leveraging Lenalidomide in multiple myeloma, lymphoma, and CLL research models.